



US00D605230S

(12) **United States Design Patent**
Langan et al.

(10) **Patent No.:** **US D605,230 S**
(45) **Date of Patent:** **** Dec. 1, 2009**

(54) **DRUG ADMINISTRATION SAFETY LABEL**

4,065,343 A 12/1977 Stumpe
4,815,768 A 3/1989 Applebaum et al.
D311,423 S 10/1990 DeSantis

(75) Inventors: **Amy E. Langan**, Glenview, IL (US);
Richard J. Kruzynski, Long Grove, IL
(US); **John A. Kollar**, Northbrook, IL
(US); **Patricia L. Miyake**, Mundelein,
IL (US); **Monique L. Kruk**, Burlington,
WI (US); **Mark F. Wagner**, Gurnee, IL
(US)

(Continued)

OTHER PUBLICATIONS

(73) Assignee: **PharMEDium Services, LLC**, Lake
Forest, IL (US)

Syringe label for Atropine sulfate, known prior to Dec. 3, 2007, 1
page.

(**) Term: **14 Years**

Label for alcohol preps, known prior to Dec. 3, 2007, 1 page.

(21) Appl. No.: **29/343,301**

IV bag label for 0.9% Sodium Chloride, known prior to Dec. 3, 2007,
1 page.

(22) Filed: **Sep. 10, 2009**

Syringe label for Labetalol Hydrochloride, known prior to Dec. 3,
2007, 1 page.

(Continued)

Related U.S. Application Data

(62) Division of application No. 29/332,179, filed on Feb.
10, 2009, now Pat. No. Des. 602,534, which is a divi-
sion of application No. 29/298,328, filed on Dec. 3,
2007, now Pat. No. Des. 588,200.

Primary Examiner—Janice E Seeger

Assistant Examiner—Mary Ann Calabrese

(74) *Attorney, Agent, or Firm*—K&L Gates LLP

(51) **LOC (9) Cl.** **19-08**

(52) **U.S. Cl.** **D20/27**

(58) **Field of Classification Search** D20/10,
D20/11, 13, 22–27, 99; 40/124.01, 124.02,
40/124.04, 299.01, 310, 325, 360, 326, 538,
40/541, 584, 594, 600, 630, 638; D19/1,
D19/9, 10; 206/63.3, 534; 235/50 A; 283/51,
283/56, 67, 71, 74, 75, 81, 99, 100, 101,
283/107–109, 114, 117; 359/2; 428/40.1,
428/40.2, 42.1–41.3, 914

See application file for complete search history.

(57)

CLAIM

The ornamental design for a drug administration safety label,
as shown and described.

DESCRIPTION

FIG. 1 is a top plan view of one embodiment of a drug
administration safety label of our new design; and,

FIG. 2 is a top plan view of an alternative embodiment of a
drug administration safety label of our new design.


In the drawings, the broken lines represent environmental
structure forming no part of the claimed design.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,722,793 A * 3/1973 Aronoff 235/50 A

1 Claim, 2 Drawing Sheets



US D605,230 S

Page 2

U.S. PATENT DOCUMENTS

5,426,520 A 6/1995 Kakae et al.
D386,212 S 11/1997 Lambert
5,924,561 A 7/1999 Baumgartner et al.
6,089,611 A 7/2000 Blank
D432,176 S 10/2000 Stevens et al.
6,299,213 B1 10/2001 Souparis
D453,529 S 2/2002 Roth
6,568,530 B2 5/2003 Takahashi et al.
D500,524 S 1/2005 Stewart et al.
D522,065 S 5/2006 Greenstein
D550,287 S 9/2007 Smart et al.
7,311,205 B2 12/2007 Adler et al.
D584,361 S * 1/2009 Davies D20/27
D588,200 S 3/2009 Langan et al.
D593,613 S * 6/2009 Langan et al. D20/27

D597,608 S * 8/2009 Langan et al. D20/27
2007/0029788 A1 2/2007 Adler
2007/0252378 A1 11/2007 Chambers

OTHER PUBLICATIONS

Label for drug vial for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.
Syringe label for Calcium Chloride, known prior to Dec. 3, 2007, 1 page.
Drug delivery device label for Phenylephrine, known prior to Dec. 3, 2007, 1 page.
Label for drug vial for Phenylephrine, known prior to Dec. 3, 2007, 1 page.
IV bag label for Fentanyl and Ropivacaine, known prior to Dec. 3, 2007, 1 page.

* cited by examiner

FIG. 1




FIG. 2

